A recent study reveals that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle plans.
Published data in a prominent health publication shows that while obese people frequently drop a large proportion of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users using these medications should be informed of the danger of rapid rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
Such speed of regain means a reversion to starting weight within about 18 months.
Comparing Treatments
The study, which reviewed 37 of studies involving thousands of participants, compared the effects of the injectable medications with other pills.
Researchers note that people who shed pounds through diet and exercise usually see a less rapid creep back—around 0.1 kg a month—after stopping.
Understanding the Fast Regain
Doctors believe the mode of action of the jabs explains the amplified regain.
These medications imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement means hunger is no longer kept in check, making overeating much more probable."
A Lifelong Disease?
Health authorities recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the significant potential of relapse, the treatment should be considered life-long.
This opinion is echoed by drug manufacturers, who say that the results "underscore the long-term character of excess weight," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the jabs report a intense resurgence of appetite.
"I experienced a switch that goes on and you become starving," recalled a patient.
This difficulty is exacerbated if patients have not developed permanent lifestyle or habit changes during therapy.
Widespread Interest
Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and maintained weight loss likely depends on ongoing behavioural changes.
